Colin Walsh is the founder and chief executive of Crescent Capital. See sector focus and contact routes.
Colin Walsh is the founder and chief executive of Crescent Capital, a Belfast-based venture capital firm he established in 1995 after six years at Hambros plc, and he has invested actively in Northern Ireland’s high-tech sector for over 20 years. His investment thesis targets technology, life sciences, and manufacturing companies exclusively within Northern Ireland, backing experienced management teams with proven track records who commit personal capital. The firm typically makes initial investments between £450,000 and £1.2 million, with total per-company exposure up to £3 million, and generally acts as a lead investor given its hands-on, partnership-oriented approach. Notable portfolio companies include Fusion Antibodies, Replify, Analytics Engines, and Acheson & Glover, on whose boards Walsh has served as director or chair. Walsh holds a distinctive point of view emphasizing operational traction, local market knowledge, and credible five- to seven-year exit scenarios, particularly trade sales, reflecting his deep governance experience across 30+ investments. He was awarded an MBE in the 2019 Queen’s Honours list for his contributions to Northern Irela
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Belfast when building a target list.
Investors like Colin Walsh · Full investor directory · Investor access · Company funding database